Impact of CYP2D6 Pharmacogenomics on Oncology: Experience at St Jude Children’s Research Hospital

DNA strand for Precision Medicine

Impact of CYP2D6 Pharmacogenomics on Oncology: Experience at St Jude Children’s Research Hospital

Abstract

CYP2D6 is an important pharmacogenetics (PGx) gene as it is involved in the metablism of ~25% of clinically prescribed drugs. Dr. Cyrine-Eliana Haidar at St Jude Children’s Research Hospital will discuss how to use CYP2D6 genetic information to guide drug dosing and improve patient care, with focus on her many years of experience in managing the medications that are important in oncology care, including ondansetron, tamoxifen, select antidepressant and pain medicines.

Date/Time: 1:00 pm CDT, Wednesday, March 24, 2021

Presenter’s Bio

Dr. Cyrine-Eliana Haidar, PharmD

Dr. Haidar is the Clinical Pharmacogenetics Coordinator at St. Jude Children’s Research Hospital. She leads the clinical implementation of PGx and is the principal investigator of the institution wide PG4KDS protocol. She is the program coordinator for St. Jude’s ASHP-accredited PGY2 Clinical Pharmacogenomics Residency and an Assistant Professor of Clinical Pharmacy at The University of Tennessee Health Science Center. She is an active member of the Clinical Pharmacogenetics Consortium (CPIC) and has authored 5 CPIC guidelines to date. Dr. Haidar is a founding member of the New Pharmacogenomics Research Network (PGRN) and is an Assistant Professor at the University of Tennessee College of Pharmacy.

Register for the webinar

Please contact us if you have any questions about the webinar or the registration process.

Register for the webinar

Learn more about how PGx improves patient outcome at St Jude Children’s Research Hospital.

 

stay connected

Sign up to receive the RPRD news and updates.